SCHEMBL7409017

SCHEMBL7409017

C=CCOc1cc(N)c(Cl)cc1C(=O)OC

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.65
HTR4 Q13639 4/20 0.45
TSHR P16473 2/20 0.45
CYP3A4 P08684 2/20 0.45
CYP1A2 P05177 2/20 0.45
CYP2D6 P10635 2/20 0.45
HTR3A P46098 2/20 0.45
CYP2C9 P11712 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
KDM4E B2RXH2 1/20 0.44
GLA P06280 1/20 0.43
FLT3 P36888 1/20 0.43
ABL1 P00519 1/20 0.42
HTR3E A5X5Y0 1/20 0.42
SLC22A1 O15245 1/20 0.42
HTR3B O95264 1/20 0.42
ALDH1A1 P00352 1/20 0.42
LMNA P02545 1/20 0.42
MPO P05164 1/20 0.42
ADRA2A P08913 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20677873 0.87 GAA (0.47) GAATSHRSMN1; SMN2KDM4EFLT3
SCHEMBL9458226 0.85 GAA (0.61) GAAHTR4TSHRCYP3A4CYP1A2
SCHEMBL7373656 0.83 GAA (0.72) GAAHTR4TSHRCYP3A4CYP1A2
SCHEMBL20393894 0.82 FLT3 (0.50) GAATSHRCYP3A4SMN1; SMN2KDM4E
SCHEMBL9458484 0.81 GAA (0.68) GAAHTR4TSHRCYP3A4CYP1A2
SCHEMBL7414760 0.81 HTT (0.50) GAATSHRSMN1; SMN2KDM4EGLA
SCHEMBL10353674 0.80 HTR4 (0.45) GAAHTR4CYP1A2CYP2D6HTR3A
SCHEMBL384749 0.79 GAA (1.00) GAAHTR4TSHRCYP3A4CYP1A2
SCHEMBL10470202 0.79 GAA (0.40) GAATSHRSMN1; SMN2KDM4EFLT3
SCHEMBL29116983 0.79 FLT3 (0.47) GAATSHRKDM4EFLT3ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1064270-A2 DISUBSTITUTED PYRAZOLINES AND TRIAZOLINES AS FACTOR XA INHIBITORS Du Pont Pharmaceuticals Company (US) 2001-01-03 EP disclosed
WO-1999050255-A2 DISUBSTITUTED PYRAZOLINES AND TRIAZOLINES AS FACTOR XA INHIBITORS DU PONT PHARMACEUTICALS COMPANY (US) 1999-10-07 WO disclosed
EP-0946528-A2 OXYGEN OR SULFUR CONTAINING 5-MEMBERED HETEROAROMATICS AS FACTOR Xa INHIBITORS Du Pont Pharmaceuticals Company (US) 1999-10-06 EP disclosed
WO-1998028282-A2 OXYGEN OR SULFUR CONTAINING 5-MEMBERED HETEROAROMATICS AS FACTOR Xa INHIBITORS DU PONT PHARMACEUTICALS COMPANY (US) 1998-07-02 WO disclosed
US-5063230-A Substituted saturated and unsaturated indole quinoline and benzazepine carboxamides and their use as pharmacological agents RHONE-POULENC RORER PHARMACEUTICALS INC. (US) 1991-11-05 US disclosed
WO-1990006113-A1 SUBSTITUTED SATURATED AND UNSATURATED INDOLE QUINOLINE AND BENZAZEPINE CARBOXAMIDES AND THEIR USE AS PHARMACOLOGICAL AGENTS RORER INTERNATIONAL (OVERSEAS) INC. (US) 1990-06-14 WO disclosed
US-4920219-A Substituted saturated and unsaturated indole quinoline and benzazepine carboxamides and their use as pharmacological agents RORER PHARMACEUTICAL CORP. (US) 1990-04-24 US disclosed
US-4914117-A ANTIDEPRESSANTS, CENTRAL NERVOUS SYSTEM ACTIVATORS; DOPAMINE ANTAGONISTS SOCIETE D'ETUDES SCIENTIFIQUES ET INDUSTRIELLE DE L'ILE-D-FRANCE (FR) 1990-04-03 US disclosed
US-4835172-A Novel benzamides, intermediates and process for the preparation and therapeutic use thereof SOCIETE D'ETUDES SCIENTIFIQUES ET INDUSTRIELLES DE L'ILE-DE-FRANCE (FR) 1989-05-30 US disclosed